N-of-One Secures $7 Million in Series B financing
The financing will be used to expand the company's leading precision medicine decision support solutions in oncology.
N-of-One has received $7 million in a Series B financing from Providence Ventures and Excel Venture Management. The financing will be used to expand the company’s R&D efforts to broaden its precision medicine clinical decision support solutions in oncology, providing physicians with a precise and scalable approach to matching patients to the most relevant treatments including clinical trials. N-of-One will also expand sales and marketing in the US and strategic global markets.
“This financing round marks a new and exciting chapter for N-of-One, and we are pleased to partner with Providence Ventures and Excel Venture Management to take the next step in solving the growing complexity of precision medicine. We look forward to collaborating with our lab and health system clients to incorporate clinical data along with the patient’s molecular profile to provide further refinement of treatment options. This is particularly important given the growing complexity of clinical trial eligibility criteria,” said Chris Cournoyer, CEO of N-of-One.
“Cancer treatment is not one size fits all, and finding the right treatment, to include appropriate clinical trials, as quickly as possible, is a top priority,” said Thomas Brown, executive director of the Swedish Cancer Institute and co-chair of Providence Health & Services’ Personalized Medicine Program. “We are thrilled to be expanding our relationship with N-of-One to scale molecular oncology decision making, bringing the promise of precision medicine to thousands of cancer patients.”
“We are delighted to be investors in N-of-One with its unrivaled technology for assisting physicians in determining the optimal treatment for their cancer patients in this era of personalized medicine,” commented board member Steve Gullans of Excel.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance